Vincristine chemotherapy trials and pharmacokinetics in tasmanian devils with tasmanian devil facial tumor disease.

Tasmanian Devil Facial Tumor Disease (DFTD) is a transmissible cancer threatening to cause the extinction of Tasmanian Devils in the wild. The aim of this study was to determine the susceptibility of the DFTD to vincristine. Escalating dosage rates of vincristine (0.05 to 0.136 mg/kg) were given to...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	David N Phalen, Angela Frimberger, Stephen Pyecroft, Sarah Peck, Colette Harmsen, Suzanneth Lola, Beatriz de Mello Mattos, Kong M Li, Andrew J McLachlan, Antony Moore
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/c0961d8036c2492d8e701f6ad689db53
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c0961d8036c2492d8e701f6ad689db53
record_format	dspace
spelling	oai:doaj.org-article:c0961d8036c2492d8e701f6ad689db532021-11-18T07:42:48ZVincristine chemotherapy trials and pharmacokinetics in tasmanian devils with tasmanian devil facial tumor disease.1932-620310.1371/journal.pone.0065133https://doaj.org/article/c0961d8036c2492d8e701f6ad689db532013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23762298/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203Tasmanian Devil Facial Tumor Disease (DFTD) is a transmissible cancer threatening to cause the extinction of Tasmanian Devils in the wild. The aim of this study was to determine the susceptibility of the DFTD to vincristine. Escalating dosage rates of vincristine (0.05 to 0.136 mg/kg) were given to Tasmanian devils in the early stages of DFTD (n = 8). None of these dosage rates impacted the outcome of the disease. A dosage rate of 0.105 mg/kg, a rate significantly higher than that given in humans or domestic animals, was found to the highest dosage rate that could be administered safely. Signs of toxicity included anorexia, vomiting, diarrhea and neutropenia. Pharmacokinetic studies showed that, as with other species, there was a rapid drop in blood concentration following a rapid intravenous infusion with a high volume of distribution (1.96 L/kg) and a relatively long elimination half life (11 h). Plasma clearance (1.8 ml/min/kg) was slower in the Tasmanian devil than in humans, suggesting that pharmacodynamics and not pharmacokinetics explain the Tasmanian devil's ability to tolerate high dosage rates of vincristine. While providing base-line data for the use of vincristine in Tasmanian devils and possibly other marsupials with vincristine susceptible cancers, these findings strongly suggest that vincristine will not be effective in the treatment of DFTD.David N PhalenAngela FrimbergerStephen PyecroftSarah PeckColette HarmsenSuzanneth LolaBeatriz de Mello MattosKong M LiAndrew J McLachlanAntony MoorePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 6, p e65133 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q David N Phalen Angela Frimberger Stephen Pyecroft Sarah Peck Colette Harmsen Suzanneth Lola Beatriz de Mello Mattos Kong M Li Andrew J McLachlan Antony Moore Vincristine chemotherapy trials and pharmacokinetics in tasmanian devils with tasmanian devil facial tumor disease.
description	Tasmanian Devil Facial Tumor Disease (DFTD) is a transmissible cancer threatening to cause the extinction of Tasmanian Devils in the wild. The aim of this study was to determine the susceptibility of the DFTD to vincristine. Escalating dosage rates of vincristine (0.05 to 0.136 mg/kg) were given to Tasmanian devils in the early stages of DFTD (n = 8). None of these dosage rates impacted the outcome of the disease. A dosage rate of 0.105 mg/kg, a rate significantly higher than that given in humans or domestic animals, was found to the highest dosage rate that could be administered safely. Signs of toxicity included anorexia, vomiting, diarrhea and neutropenia. Pharmacokinetic studies showed that, as with other species, there was a rapid drop in blood concentration following a rapid intravenous infusion with a high volume of distribution (1.96 L/kg) and a relatively long elimination half life (11 h). Plasma clearance (1.8 ml/min/kg) was slower in the Tasmanian devil than in humans, suggesting that pharmacodynamics and not pharmacokinetics explain the Tasmanian devil's ability to tolerate high dosage rates of vincristine. While providing base-line data for the use of vincristine in Tasmanian devils and possibly other marsupials with vincristine susceptible cancers, these findings strongly suggest that vincristine will not be effective in the treatment of DFTD.
format	article
author	David N Phalen Angela Frimberger Stephen Pyecroft Sarah Peck Colette Harmsen Suzanneth Lola Beatriz de Mello Mattos Kong M Li Andrew J McLachlan Antony Moore
author_facet	David N Phalen Angela Frimberger Stephen Pyecroft Sarah Peck Colette Harmsen Suzanneth Lola Beatriz de Mello Mattos Kong M Li Andrew J McLachlan Antony Moore
author_sort	David N Phalen
title	Vincristine chemotherapy trials and pharmacokinetics in tasmanian devils with tasmanian devil facial tumor disease.
title_short	Vincristine chemotherapy trials and pharmacokinetics in tasmanian devils with tasmanian devil facial tumor disease.
title_full	Vincristine chemotherapy trials and pharmacokinetics in tasmanian devils with tasmanian devil facial tumor disease.
title_fullStr	Vincristine chemotherapy trials and pharmacokinetics in tasmanian devils with tasmanian devil facial tumor disease.
title_full_unstemmed	Vincristine chemotherapy trials and pharmacokinetics in tasmanian devils with tasmanian devil facial tumor disease.
title_sort	vincristine chemotherapy trials and pharmacokinetics in tasmanian devils with tasmanian devil facial tumor disease.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/c0961d8036c2492d8e701f6ad689db53
work_keys_str_mv	AT davidnphalen vincristinechemotherapytrialsandpharmacokineticsintasmaniandevilswithtasmaniandevilfacialtumordisease AT angelafrimberger vincristinechemotherapytrialsandpharmacokineticsintasmaniandevilswithtasmaniandevilfacialtumordisease AT stephenpyecroft vincristinechemotherapytrialsandpharmacokineticsintasmaniandevilswithtasmaniandevilfacialtumordisease AT sarahpeck vincristinechemotherapytrialsandpharmacokineticsintasmaniandevilswithtasmaniandevilfacialtumordisease AT coletteharmsen vincristinechemotherapytrialsandpharmacokineticsintasmaniandevilswithtasmaniandevilfacialtumordisease AT suzannethlola vincristinechemotherapytrialsandpharmacokineticsintasmaniandevilswithtasmaniandevilfacialtumordisease AT beatrizdemellomattos vincristinechemotherapytrialsandpharmacokineticsintasmaniandevilswithtasmaniandevilfacialtumordisease AT kongmli vincristinechemotherapytrialsandpharmacokineticsintasmaniandevilswithtasmaniandevilfacialtumordisease AT andrewjmclachlan vincristinechemotherapytrialsandpharmacokineticsintasmaniandevilswithtasmaniandevilfacialtumordisease AT antonymoore vincristinechemotherapytrialsandpharmacokineticsintasmaniandevilswithtasmaniandevilfacialtumordisease
_version_	1718423124835303424

Vincristine chemotherapy trials and pharmacokinetics in tasmanian devils with tasmanian devil facial tumor disease.

Ejemplares similares